Key terms
About APLT
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest APLT news
Apr 15
5:12pm ET
Applied Therapeutics Welcomes Dale Hooks as New CCO
Apr 15
7:05am ET
Applied Therapeutics appoints Dale Hooks as CCO
Apr 14
2:36am ET
RBC Capital Sticks to Their Buy Rating for Applied Therapeutics (APLT)
Apr 04
7:21am ET
Applied Therapeutics to present data from study of caficrestat in DbCM
Apr 03
2:01am ET
Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Applied Therapeutics (APLT) and Vincerx Pharma Inc (VINC)
Mar 28
4:54pm ET
Applied Therapeutics down 11% after extended FDA review for govorestat NDA
Mar 28
4:34pm ET
Applied Therapeutics: FDA extends review period for NDA for govorestat
Mar 25
4:08pm ET
Applied Therapeutics initiated with an Outperform at RBC Capital
Mar 22
4:33pm ET
Applied Therapeutics files to sell 14.29M shares of common stock for holders
Mar 20
8:46am ET
Largest borrow rate increases among liquid names
Mar 13
2:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 11
8:32am ET
Applied Therapeutics Reveals Strategy and Positive Trial Update
Mar 11
12:40am ET
Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Xeris Pharmaceuticals (XERS) and Arcturus Therapeutics (ARCT)
Mar 08
1:02am ET
Applied Therapeutics’ New Accounting & Financial Operations Risk – A Cause for Worry?
Mar 06
7:49am ET
Applied Therapeutics price target raised to $12 from $4 at UBS
Mar 06
7:08am ET
Applied Therapeutics reports FY23 EPS ($1.42), consensus ($1.42)
Mar 01
1:19am ET
Optimistic Buy Rating for Applied Therapeutics Amid Favorable Drug Approval Prospects and Strong Financial Position
Mar 01
1:05am ET
Buy Rating Affirmed for Applied Therapeutics as FDA Prioritizes Govorestat, Signaling Strong Market Prospects
Feb 28
8:17am ET
Applied Therapeutics to sell 12.3M shares at $7.00 in private placement
Feb 28
8:05am ET
Applied Therapeutics receives FDA acceptance, Priority Review for govorestat NDA
Feb 22
6:17am ET
Applied Therapeutics initiated with an Outperform at Leerink
Feb 16
7:24am ET
Analyst Upgrades Applied Therapeutics Target to $7 on SORD Program Progress and Govorestat Pricing Reassessment
Feb 16
6:57am ET
Applied Therapeutics price target raised to $7 from $5 at Citi
Feb 15
7:22am ET
Applied Therapeutics’ Govorestat Shows Promise in Phase 3 Trial
Feb 15
7:14am ET
Applied Therapeutics announces results from 12-month interim analysis of AT-007
No recent press releases are available for APLT
APLT Financials
Key terms
Ad Feedback
APLT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
APLT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range